Cargando…

A three-country comparison of psychotropic medication prevalence in youth

BACKGROUND: The study aims to compare cross-national prevalence of psychotropic medication use in youth. METHODS: A population-based analysis of psychotropic medication use based on administrative claims data for the year 2000 was undertaken for insured enrollees from 3 countries in relation to age...

Descripción completa

Detalles Bibliográficos
Autores principales: Zito, Julie M, Safer, Daniel J, Berg, Lolkje TW de Jong-van den, Janhsen, Katrin, Fegert, Joerg M, Gardner, James F, Glaeske, Gerd, Valluri, Satish C
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2569908/
https://www.ncbi.nlm.nih.gov/pubmed/18817536
http://dx.doi.org/10.1186/1753-2000-2-26
_version_ 1782160089198624768
author Zito, Julie M
Safer, Daniel J
Berg, Lolkje TW de Jong-van den
Janhsen, Katrin
Fegert, Joerg M
Gardner, James F
Glaeske, Gerd
Valluri, Satish C
author_facet Zito, Julie M
Safer, Daniel J
Berg, Lolkje TW de Jong-van den
Janhsen, Katrin
Fegert, Joerg M
Gardner, James F
Glaeske, Gerd
Valluri, Satish C
author_sort Zito, Julie M
collection PubMed
description BACKGROUND: The study aims to compare cross-national prevalence of psychotropic medication use in youth. METHODS: A population-based analysis of psychotropic medication use based on administrative claims data for the year 2000 was undertaken for insured enrollees from 3 countries in relation to age group (0–4, 5–9, 10–14, and 15–19), gender, drug subclass pattern and concomitant use. The data include insured youth aged 0–19 in the year 2000 from the Netherlands (n = 110,944), Germany (n = 356,520) and the United States (n = 127,157). RESULTS: The annual prevalence of any psychotropic medication in youth was significantly greater in the US (6.7%) than in the Netherlands (2.9%) and in Germany (2.0%). Antidepressant and stimulant prevalence were 3 or more times greater in the US than in the Netherlands and Germany, while antipsychotic prevalence was 1.5–2.2 times greater. The atypical antipsychotic subclass represented only 5% of antipsychotic use in Germany, but 48% in the Netherlands and 66% in the US. The less commonly used drugs e.g. alpha agonists, lithium and antiparkinsonian agents generally followed the ranking of US>Dutch>German youth with very rare (less than 0.05%) use in Dutch and German youth. Though rarely used, anxiolytics were twice as common in Dutch as in US and German youth. Prescription hypnotics were half as common as anxiolytics in Dutch and US youth and were very uncommon in German youth. Concomitant drug use applied to 19.2% of US youth which was more than double the Dutch use and three times that of German youth. CONCLUSION: Prominent differences in psychotropic medication treatment patterns exist between youth in the US and Western Europe and within Western Europe. Differences in policies regarding direct to consumer drug advertising, government regulatory restrictions, reimbursement policies, diagnostic classification systems, and cultural beliefs regarding the role of medication for emotional and behavioral treatment are likely to account for these differences.
format Text
id pubmed-2569908
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-25699082008-10-18 A three-country comparison of psychotropic medication prevalence in youth Zito, Julie M Safer, Daniel J Berg, Lolkje TW de Jong-van den Janhsen, Katrin Fegert, Joerg M Gardner, James F Glaeske, Gerd Valluri, Satish C Child Adolesc Psychiatry Ment Health Research BACKGROUND: The study aims to compare cross-national prevalence of psychotropic medication use in youth. METHODS: A population-based analysis of psychotropic medication use based on administrative claims data for the year 2000 was undertaken for insured enrollees from 3 countries in relation to age group (0–4, 5–9, 10–14, and 15–19), gender, drug subclass pattern and concomitant use. The data include insured youth aged 0–19 in the year 2000 from the Netherlands (n = 110,944), Germany (n = 356,520) and the United States (n = 127,157). RESULTS: The annual prevalence of any psychotropic medication in youth was significantly greater in the US (6.7%) than in the Netherlands (2.9%) and in Germany (2.0%). Antidepressant and stimulant prevalence were 3 or more times greater in the US than in the Netherlands and Germany, while antipsychotic prevalence was 1.5–2.2 times greater. The atypical antipsychotic subclass represented only 5% of antipsychotic use in Germany, but 48% in the Netherlands and 66% in the US. The less commonly used drugs e.g. alpha agonists, lithium and antiparkinsonian agents generally followed the ranking of US>Dutch>German youth with very rare (less than 0.05%) use in Dutch and German youth. Though rarely used, anxiolytics were twice as common in Dutch as in US and German youth. Prescription hypnotics were half as common as anxiolytics in Dutch and US youth and were very uncommon in German youth. Concomitant drug use applied to 19.2% of US youth which was more than double the Dutch use and three times that of German youth. CONCLUSION: Prominent differences in psychotropic medication treatment patterns exist between youth in the US and Western Europe and within Western Europe. Differences in policies regarding direct to consumer drug advertising, government regulatory restrictions, reimbursement policies, diagnostic classification systems, and cultural beliefs regarding the role of medication for emotional and behavioral treatment are likely to account for these differences. BioMed Central 2008-09-25 /pmc/articles/PMC2569908/ /pubmed/18817536 http://dx.doi.org/10.1186/1753-2000-2-26 Text en Copyright © 2008 Zito et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Zito, Julie M
Safer, Daniel J
Berg, Lolkje TW de Jong-van den
Janhsen, Katrin
Fegert, Joerg M
Gardner, James F
Glaeske, Gerd
Valluri, Satish C
A three-country comparison of psychotropic medication prevalence in youth
title A three-country comparison of psychotropic medication prevalence in youth
title_full A three-country comparison of psychotropic medication prevalence in youth
title_fullStr A three-country comparison of psychotropic medication prevalence in youth
title_full_unstemmed A three-country comparison of psychotropic medication prevalence in youth
title_short A three-country comparison of psychotropic medication prevalence in youth
title_sort three-country comparison of psychotropic medication prevalence in youth
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2569908/
https://www.ncbi.nlm.nih.gov/pubmed/18817536
http://dx.doi.org/10.1186/1753-2000-2-26
work_keys_str_mv AT zitojuliem athreecountrycomparisonofpsychotropicmedicationprevalenceinyouth
AT saferdanielj athreecountrycomparisonofpsychotropicmedicationprevalenceinyouth
AT berglolkjetwdejongvanden athreecountrycomparisonofpsychotropicmedicationprevalenceinyouth
AT janhsenkatrin athreecountrycomparisonofpsychotropicmedicationprevalenceinyouth
AT fegertjoergm athreecountrycomparisonofpsychotropicmedicationprevalenceinyouth
AT gardnerjamesf athreecountrycomparisonofpsychotropicmedicationprevalenceinyouth
AT glaeskegerd athreecountrycomparisonofpsychotropicmedicationprevalenceinyouth
AT vallurisatishc athreecountrycomparisonofpsychotropicmedicationprevalenceinyouth
AT zitojuliem threecountrycomparisonofpsychotropicmedicationprevalenceinyouth
AT saferdanielj threecountrycomparisonofpsychotropicmedicationprevalenceinyouth
AT berglolkjetwdejongvanden threecountrycomparisonofpsychotropicmedicationprevalenceinyouth
AT janhsenkatrin threecountrycomparisonofpsychotropicmedicationprevalenceinyouth
AT fegertjoergm threecountrycomparisonofpsychotropicmedicationprevalenceinyouth
AT gardnerjamesf threecountrycomparisonofpsychotropicmedicationprevalenceinyouth
AT glaeskegerd threecountrycomparisonofpsychotropicmedicationprevalenceinyouth
AT vallurisatishc threecountrycomparisonofpsychotropicmedicationprevalenceinyouth